Risk factors
Curis (CRIS) risk factors
Item 1A of every Curis Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors57 risks8 new8 dropped17 reworded
Curis faces intense competition for its lead drug emavusertib across multiple oncology indications. The company added new risks regarding FDA funding and potential 100% tariffs on imported branded drugs. Curis received a Nasdaq delisting notice for failing minimum bid price requirements.
Filed Mar 24, 2026 - FY2024 10-K risk factors57 risks
Curis faces going concern doubts and net losses, with $20.0 million in cash as of December 31, 2024. The business relies heavily on the clinical success and commercialization of emavusertib. Royalty revenue depends on Genentech and Roche sales of Erivedge.
Filed Mar 31, 2025